Literature DB >> 7794284

Human proadrenomedullin N-terminal 20 peptide in pheochromocytoma and normal adrenal medulla.

K Kuwasako1, K Kitamura, Y Ichiki, J Kato, K Kangawa, H Matsuo, T Eto.   

Abstract

Proadrenomedullin N-terminal 20 peptide (PAMP) is a novel hypotensive peptide found in adrenomedullin precursor. Using a radioimmunoassay for human PAMP, we purified immunoreactive PAMP (ir-PAMP) from human pheochromocytoma and determined its complete amino acid sequence. The major component of PAMP-like immunoreactivity was found to be PAMP [1-20] NH2 with an amino acid sequence identical to that of the deduced amino acid sequence by cDNA analysis. Both ir-PAMP and ir-adrenomedullin were found to be abundant in normal adrenal medulla as well as pheochromocytoma tissue arising from adrenal medulla, and there was a significantly (p < 0.05) positive correlation between ir-adrenomedullin and ir-PAMP concentrations in these tissues. However, the PAMP/adrenomedullin ratio in pheochromocytoma tissues (0.197 +/- 0.013) was significantly (p < 0.005) lower than that in adrenal medullae (0.384 +/- 0.041). The present data indicate that PAMP is biosynthesized from adrenomedullin precursor, but the biosynthesis or metabolism of PAMP in pheochromocytoma may be different from that of normal adrenal medulla.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794284     DOI: 10.1006/bbrc.1995.1867

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Effect of vasoactive peptides in Tetrahymena: chemotactic activities of adrenomedullin, proadrenomedullin N-terminal 20 peptide (PAMP) and calcitonin gene-related peptide (CGRP).

Authors:  László Kőhidai; Katalin Tóth; Paul Samotik; Kiran Ranganathan; Orsolya Láng; Miklós Tóth; Heikki Ruskoaho
Journal:  Mol Cell Biochem       Date:  2015-10-19       Impact factor: 3.396

2.  Adrenomedullin expression in the human endometrium.

Authors:  J B Laoag-Fernandez; T Otani; T Maruo
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.